A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2032-11-30
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is
effective and safe in delaying cancer return in participants with early-stage non-small cell
lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned
to placebo and stop the study drug because their disease comes back or gets worse have the
option to potentially crossover to selpercatinib. Participation could last up to three years.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company Loxo Oncology, Inc.
Collaborators:
Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company